IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v22y2021i9d10.1007_s10198-021-01315-y.html
   My bibliography  Save this article

Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis

Author

Listed:
  • Ian Grady

    (North Valley Breast Clinic)

  • Sean Grady

    (North Valley Breast Clinic)

  • Nailya Chanisheva

    (North Valley Breast Clinic)

Abstract

Introduction Breast cancer treatment includes increasingly complex and expensive treatments. Accordingly, the current estimates of the cost of breast cancer treatment are out of date. Methods The SEER-Medicare Data Link provided 142,837,978 paid Medicare claims from 398,148 female beneficiaries between the ages of 22 and 110 diagnosed with breast cancer between 2007 and 2016. These claims were compared with 153,071,044 claims from 443,952 Medicare beneficiaries without a cancer diagnosis. The total, fully adjudicated, amounts for each claim were summed to determine total treatment cost for each beneficiary. These costs were then aggregated by year after diagnosis and stage at diagnosis. The actuarial survival of beneficiaries with cancer was calculated using the Kaplan–Meier method. Results Mean costs for the control group were $8,019 per year. The 10-year cost of cancer treatment in Medicare beneficiaries was directly related to stage at diagnosis and ranged from $103,573 for stage 0 cancers to $376,573 for stage 4 cancers. The highest cost occurred during the first 2 years after diagnosis, the time of the beneficiary’s initial treatment. Following the first 2 years, healthcare costs remained elevated for at least 10 years after diagnosis. Conclusions The 10-year treatment cost of female Medicare beneficiaries with breast cancer increases with increasing stage at diagnosis. Any effective screening technology that reduces stage at diagnosis will result in significant treatment cost savings to the Medicare program.

Suggested Citation

  • Ian Grady & Sean Grady & Nailya Chanisheva, 2021. "Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1365-1370, December.
  • Handle: RePEc:spr:eujhec:v:22:y:2021:i:9:d:10.1007_s10198-021-01315-y
    DOI: 10.1007/s10198-021-01315-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01315-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-021-01315-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Li Sun & Rosa Legood & Isabel dos-Santos-Silva & Shivani Mathur Gaiha & Zia Sadique, 2018. "Global treatment costs of breast cancer by stage: A systematic review," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-14, November.
    2. Xiaotong Niu & Melinda Buntin & Joyce Manchester, 2015. "Changes in Medicare Spending per Beneficiary by Age: Working Paper 2015-08," Working Papers 51027, Congressional Budget Office.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Katharina M. D. Merollini & Louisa G. Gordon & Yiu M. Ho & Joanne F. Aitken & Michael G. Kimlin, 2022. "Cancer Survivors’ Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q)," IJERPH, MDPI, vol. 19(15), pages 1-17, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hofmarcher, Thomas & Lindgren, Peter & Wilking, Nils, 2022. "Cancer Care in Türkiye in a European Context," IHE Report / IHE Rapport 2022:10, IHE - The Swedish Institute for Health Economics.
    2. Michela Franchini & Stefania Pieroni & Edgardo Montrucchio & Jacopo Nori Cucchiari & Cosimo Di Maggio & Enrico Cassano & Brunella Di Nubila & Gian Marco Giuseppetti & Alberto Nicolucci & Gianfranco Sc, 2021. "The P.I.N.K. Study Approach for Supporting Personalized Risk Assessment and Early Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(5), pages 1-15, March.
    3. Iasmina Petrovici & Mihaela Ionica & Octavian C. Neagoe, 2021. "Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(8), pages 1-10, April.
    4. Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski, 2021. "Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review," PharmacoEconomics, Springer, vol. 39(5), pages 485-502, May.
    5. Barkowski, Scott & Jun, Dajung & Zhang, Yuting, 2022. "Medicaid Expansion Spillover Effects on Health Care Consumption and Coverage: Evidence from Medicare Administrative Data," MPRA Paper 112178, University Library of Munich, Germany.
    6. Lorna Wills & Diana Nagarwalla & Clare Pearson & Sean McPhail & Rose Hinchliffe & Ben Sharpless & Fahmina Fardus-Reid & Lyndsy Ambler & Samantha Harrison & Jon Shelton, 2024. "Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 763-774, July.
    7. Francesco Saverio Mennini & Marco Trabucco Aurilio & Simone Gazzillo & Claudia Nardone & Paolo Sciattella & Andrea Marcellusi & Raffaele Migliorini & Valerio Sciannamea & Andrea Piccioni & Matteo Bolc, 2021. "An Analysis of the Social and Economic Costs of Breast Cancer in Italy," IJERPH, MDPI, vol. 18(17), pages 1-12, August.
    8. Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson, 2022. "Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand," PharmacoEconomics - Open, Springer, vol. 6(4), pages 539-548, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:22:y:2021:i:9:d:10.1007_s10198-021-01315-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.